← Back to Search

Anti-Vaping Messages for Reducing Nicotine Use in Young Adults

N/A

Recruiting

Research Sponsored by University of Georgia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

Study Summary

This trial will test if anti-vaping PSAs can reduce nicotine use in young adult vapers; participants will receive weekly online surveys, view PSAs, and be biochemically tested.

Who is the study for?

This trial is for young adult vapers who haven't smoked cigarettes in the past month, have used e-cigarettes on at least 3 days in that time, and can safely undergo MRI scans. It's not for those with recent cigarette use, major health disorders, or MRI contraindications.Check my eligibility

What is being tested?

The study tests how anti-vaping messages affect young vapers' brains and behavior over a year. Participants will see regular or flavor-specific anti-vaping PSAs while their brain activity is monitored using fMRI. They'll switch message types after 6 months.See study design

What are the potential side effects?

There are no direct side effects from the interventions since they involve exposure to public service announcements and surveys. However, undergoing an fMRI may include discomfort from staying still in a confined space.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Carbon monoxide

Self-report monthly smoking severity

Self-report monthly vaping severity

+1 more

Secondary outcome measures

Cigarette smoking urge

Electronic cigarette user

Message effectiveness perceptions

+4 more

Trial Design

3Treatment groups

Experimental Treatment

Group I: No message exposure (control condition)Experimental Treatment1 Intervention

Participants will not be receiving any PSA exposure over the 12 months.

Group II: Message exposure (sequence: regular PSAs then flavor PSAs)Experimental Treatment1 Intervention

Participants randomly assigned to this arm will receive weekly emails and text messages of regular PSAs (i.e., focused in general on the negative consequences of vaping) for the first 6 months of the study, and will then receive weekly emails and text messages of flavor PSAs (i.e., focused specifically on harms and negative consequences associated with vaping flavored e-cigarette products) for the second 6 months of the study.

Group III: Message exposure (sequence: flavor PSAs then regular PSAs)Experimental Treatment1 Intervention

Participants randomly assigned to this arm will receive weekly emails and text messages of flavor PSAs (i.e., focused specifically on harms and negative consequences associated with vaping flavored e-cigarette products) for the first 6 months of the study, and will then receive weekly emails and text messages of regular PSAs (i.e., focused in general on the negative consequences of vaping) for the second 6 months of the study.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of GeorgiaLead Sponsor

102 Previous Clinical Trials

34,582 Total Patients Enrolled

Media Library

Message exposure (sequence: regular PSAs then flavor PSAs) Clinical Trial Eligibility Overview. Trial Name: NCT05447325 — N/A

Message Exposure Sequence (Regular Then Flavor) Research Study Groups: Message exposure (sequence: regular PSAs then flavor PSAs), Message exposure (sequence: flavor PSAs then regular PSAs), No message exposure (control condition)

Message Exposure Sequence (Regular Then Flavor) Clinical Trial 2023: Message exposure (sequence: regular PSAs then flavor PSAs) Highlights & Side Effects. Trial Name: NCT05447325 — N/A

Message exposure (sequence: regular PSAs then flavor PSAs) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05447325 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this experiment seek to recruit participants aged 25 and over?

"This medical trial is open to individuals over the age of consent, but younger than 25 years old."

Answered by AI

Are there any participants being recruited for this experiment currently?

"This clinical study, which was initially posted on the 1st of August 2022, is actively seeking participants. Its last update occurred on April 13th 2023 and can be found in detail at clinicialtrials.gov"

Answered by AI

What is the current sample size for this trial?

"Yes, according to clinicaltrials.gov records, the medical trial is actively in search of eligible individuals. It was initially posted on August 1st 2022 and was last updated April 13th 2023. At this moment 180 participants are sought from a single site."

Answered by AI

Could I potentially participate in this clinical assessment?

"The criteria to be considered for this medical trial involves having no prior exposure and being between the ages of 18-25. Altogether, 180 participants must join the research."

Answered by AI

What is the purpose of this clinical research project?

"This medical trial, which will span a period of 12 months, aims to measure the severity of vaping through self-reporting. Additionally, secondary objectives include estimating frequency of other tobacco use with timeline follow back measures, evaluating nicotine dependence by way of Penn State Electronic Cigarette Dependence Index (PSECDI), and assessing smoking intention via three survey items."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Neuroimaging Approaches to Improve Prediction of Smoking Initiation and Nicotine Use Escalation Among Young Adult Electronic Nicotine Delivery Systems Users

Jiaying Liu 2022. "Neuroimaging Approaches to Improve Prediction of Smoking Initiation and Nicotine Use Escalation Among Young Adult Electronic Nicotine Delivery Systems Users". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05447325.